NCT03487263View on ClinicalTrials.gov

Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 1, 2017

Primary Completion Date

April 18, 2018

Study Completion Date

December 30, 2018

Conditions
Motor Neuron DiseaseAmyotrophic Lateral Sclerosis
Interventions
BIOLOGICAL

IC14

chimeric monoclonal antibody against human IC14

Trial Locations (1)

4006

Royal Brisbane and Women's Hospital, Herston

Sponsors
All Listed Sponsors
collaborator

Royal Brisbane and Women's Hospital

OTHER_GOV

lead

Implicit Bioscience

INDUSTRY